1-3 of 3
Zeng Yun
Close
Sort by
Journal Articles

Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

Wenjiao Tang, Yan Li, Qiushi Liang, Ying Qu, Li Zhang, Yuzhang Liu, Baijun Fang, Zeng Yun, Xiaobo Du, Yaming Xi, Ting Wang, Xin Li, Jie Huang, Wenbin Qian, Zhen Cai, Qingwei Zhao, Yue Lv, Ting Niu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4396–4397.
https://doi.org/10.1182/blood-2022-168091
Published: 2022
Journal Articles

Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial

Yu Hu, Renchi Yang, Ting Niu, Heng Mei, Liu Xiaofan, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, De-Pei Wu, Xuliang Shen, Jie Jin, Jianmin Luo, Zeng Yun, Xin Zhou, Ruixiang Xiang, Zhongxing Jiang, Yuansong Bai, Junye Xiong, Runzi Li, Jianjun Zou
Journal: Blood
Blood (2022) 140 (Supplement 1): 5543–5545.
https://doi.org/10.1182/blood-2022-162945
Published: 2022
Journal Articles

FINAL Results of an Phase, Multicenter, Randomied, Controlled OPEN LEVEL Trial: Decitabine Therapy in Patients with Myelodysplastic Syndromes

Zonghong Shao, MD, Hui Liu, Hao Jiang, Hongyan Tong, PhD, Ruixiang Xiang, Linhua Yang, Hongguo Zhao, MD, Jian Ouyang, MD, Hai Bai, Hui Sun, Li Hou, Ming Jiang, Zeng Yun, MD PhD, Zhuogang Liu, Aibin Liang, MD PhD, Yinghua Xie, Kang Yu, MD, Zhimin Zhai, MD, Li Liu
Journal: Blood
Blood (2018) 132 (Supplement 1): 3865.
https://doi.org/10.1182/blood-2018-99-116041
Published: 2018